Volume 26, Issue 1 (Spring 2022)                   2022, 26(1): 1-8 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sadabadi F, Shahi M, Darroudi S, Rastgar Moghadam A, Heidari-Bakavoli S, Porsa A, et al . Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study. Journal of Inflammatory Diseases. 2022; 26 (1) :1-8
URL: http://journal.qums.ac.ir/article-1-3278-en.html
1- Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research, Razavi Khorasan Branch, Mashhad, Iran.
3- Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4- Department of Biology, School of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran.
5- Department of Biostatistics & Epidemiology, Management & Social Determinants of Health Research Center, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
6- Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
7- Department of Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
8- Department of Medical Education, School of Brighton & Sussex Medical, Brighton, UK.
9- Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , ghayourm@mums.ac.ir
Abstract:   (1755 Views)

Background: Heat shock protein 27 (HSP27) is found in several cell types of adults, such as cardiomyocytes, and endothelial cells. It is expressed in response to different cellular stress conditions. HSP27 decreases the levels of reactive oxygen species (ROS) and dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS). 
Objective: Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction
Methods: This population-based case-control study was conducted in 2018. We investigated serum anti-HSP27 antibody titers in all participants with dyslipidemia from the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study (n=8141) and those who were healthy in terms of dyslipidemia (n=1637) using an in-house enzyme-linked immune sorbent assay (ELISA) in individuals with dyslipidemia.
Findings: Anti-HSP27 titers were significantly lower in individuals with dyslipidemia compared to people without dyslipidemia (P=0.036).
Conclusion: Our results revealed that the anti-HSP27 antibody titer was lower in the participants with dyslipidemia than in the negative group. However, there may be a confounding effect of drug therapy. In a subgroup of dyslipidemic subjects, we observed lower anti-HSP27 antibody titers in patients treated with some drugs (statins or corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], or anti-diabetic and anti-hypertensive) compared to subjects untreated with these drugs.

Full-Text [PDF 714 kb]   (463 Downloads) |   |   Full-Text (HTML)  (458 Views)  
Type of Study: Research | Subject: Biochemistry

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb